Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
Other Sizes |
|
ln Vitro |
PKA kinase and myelin basic protein (MBP), the full-length protein substrate, were treated with ATP-polyamine-biotin (APB). Kinase was required for the detection of biotinylation. Additionally, in the presence of the kinase inhibitor staurosporine, in the absence of ATP-polyamine-biotin, or during acid incubation, MBP biotinylation is lost as a result of cleavage of the phosphoramidate bond. It is only in the presence of APB co-substrate that the biotinylated Kemp peptide product is detected [1].
|
---|---|
References |
Molecular Formula |
C32H58N11O14P3S
|
---|---|
Molecular Weight |
945.8545
|
Exact Mass |
945.309
|
CAS # |
1800401-93-7
|
PubChem CID |
118704767
|
Appearance |
White to off-white solid powder
|
Density |
1.8±0.1 g/cm3
|
Index of Refraction |
1.730
|
LogP |
-3.53
|
Hydrogen Bond Donor Count |
10
|
Hydrogen Bond Acceptor Count |
22
|
Rotatable Bond Count |
27
|
Heavy Atom Count |
61
|
Complexity |
1590
|
Defined Atom Stereocenter Count |
7
|
SMILES |
CN(CCCCN(C)CCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)CCCNC(=O)CCCC[C@H]4[C@@H]5[C@H](CS4)NC(=O)N5
|
InChi Key |
MODMQMYTNMWWCS-MCINONILSA-N
|
InChi Code |
InChI=1S/C32H58N11O14P3S/c1-41(15-7-11-34-24(44)10-4-3-9-23-25-21(18-61-23)39-32(47)40-25)13-5-6-14-42(2)16-8-12-38-58(48,49)56-60(52,53)57-59(50,51)54-17-22-27(45)28(46)31(55-22)43-20-37-26-29(33)35-19-36-30(26)43/h19-23,25,27-28,31,45-46H,3-18H2,1-2H3,(H,34,44)(H,50,51)(H,52,53)(H2,33,35,36)(H2,38,48,49)(H2,39,40,47)/t21-,22+,23-,25-,27+,28+,31+/m0/s1
|
Chemical Name |
N-[3-[4-[3-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]propyl-methylamino]butyl-methylamino]propyl]-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxyphosphonamidic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~6 mg/mL (~6.34 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 7.69 mg/mL (8.13 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with heating and sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.0573 mL | 5.2863 mL | 10.5725 mL | |
5 mM | 0.2115 mL | 1.0573 mL | 2.1145 mL | |
10 mM | 0.1057 mL | 0.5286 mL | 1.0573 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.